Parkinson's disease is a progressive neurodegenerative disorder that is common, age-related and chronic.
It is caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain.
Onset of symptoms and progression of the disease is gradual.
Motor signs and symptoms include resting tremor, rigidity, bradykinesia and postural instability.
Parkinson's disease dementia indicates loss of intellectual functions
including memory, significant deterioration in the ability to carry out
day-to-day activities and changes in social behavior are often noted.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
An active lifestyle, regardless of vascular risk, may delay the progression of Alzheimer’s disease (AD) by slowing down cognitive decline and neurodegeneration, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).